High ADH levels have been associated with CKD progression, most notably in so-called Mesoamerican nephropathy and in polycystic kidney disease, that is now treated with an ADH receptor V2 blocker, tolvaptan (Carriazo et al., 2019; Perez-Gomez et al., 2018). This evidence concerns the gene AVP and Nephropathy.